We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Read MoreHide Full Article
Key Takeaways
Alkermes' proprietary product sales rose 34% year over year to $411.7 million in Q2 2026.
Alkermes' Vivitrol, Aristada and Lybalvi all posted higher sales in the first six months of 2026.
Alixorexton could add a long-term growth opportunity, with clinical milestones expected later in 2026.
Shares of Alkermes (ALKS - Free Report) have risen 26.5% in the past three months, driven by strong sales growth across its proprietary product portfolio and continued progress in its clinical pipeline.
Alkermes’ proprietary products include Vivitrol for alcohol and opioid dependence, Aristada for schizophrenia, Lybalvi for schizophrenia and bipolar I disorder and the newly acquired sleep disorder drug, Lumryz.
The company recently reported second-quarter 2026 results, wherein sales of its proprietary products portfolio grew 34% year over year to $411.7 million. Importantly, sales exceeded management’s guided range of $385-$405 million for the quarter.
Strong demand for its proprietary products is supporting Alkermes’ top-line growth and driving the stock, with the company expecting continued momentum through the remainder of 2026.
Year to date, shares of Alkermes have rallied 75.9% compared with the industry’s rise of 6.4%.
Image Source: Zacks Investment Research
ALKS’ Strong Product Portfolio Aids Growth
In the first six months of 2026, Vivitrol and Aristada generated sales of $236.9 million and $190.5 million, respectively, up 6.4% and 9% year over year. Sales of both drugs benefited from underlying demand.
Notably, growth in the alcohol-dependence treatment market has helped drive new patients toward Vivitrol, while Aristada continues to generate steady sales.
In the first six months of 2026, Lybalvi generated sales of $186.3 million, up 20.7% year over year, driven by an increase in total prescriptions.
Alkermes added the narcolepsy drug Lumryz to its portfolio following the acquisition of Avadel Pharmaceuticals in February 2026. Lumryz generated $136.1 million in revenues during the first six months of 2026 following its addition to Alkermes’ portfolio.
Reflecting the growing momentum across its product portfolio, Alkermes expects Vivitrol sales to be in the range of $460-$480 million, while Aristada sales are anticipated in the range of $365-$385 million in 2026.
Lybalvi sales are expected to be in the range of $380-$400 million, while Lumryz sales are expected to be in the range of $315-$335 million in 2026.
ALKS' Ongoing Pipeline Development Activities
Alkermes is developing alixorexton, a novel, investigational, oral, selective orexin 2 receptor agonist for treating narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) in late-stage studies, as well as idiopathic hypersomnia (IH) in a mid-stage study.
In June 2026, the FDA granted orphan drug designation (ODD) to alixorexton for the treatment of IH. The European Commission also granted ODD to alixorexton for the treatment of patients with narcolepsy.
With certain clinical milestones expected later this year, successful development and potential approval of alixorexton could provide Alkermes with an additional long-term growth opportunity.
The consistent growth of its proprietary product portfolio, coupled with continued clinical progress with alixorexton, provides Alkermes with multiple growth drivers. These catalysts could support the company’s long-term growth prospects and help maintain positive momentum in the stock.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have gained 0.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 154.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
ALKS Stock Rises 27% in 3 Months: Here's What You Should Know
Key Takeaways
Shares of Alkermes (ALKS - Free Report) have risen 26.5% in the past three months, driven by strong sales growth across its proprietary product portfolio and continued progress in its clinical pipeline.
Alkermes’ proprietary products include Vivitrol for alcohol and opioid dependence, Aristada for schizophrenia, Lybalvi for schizophrenia and bipolar I disorder and the newly acquired sleep disorder drug, Lumryz.
The company recently reported second-quarter 2026 results, wherein sales of its proprietary products portfolio grew 34% year over year to $411.7 million. Importantly, sales exceeded management’s guided range of $385-$405 million for the quarter.
Strong demand for its proprietary products is supporting Alkermes’ top-line growth and driving the stock, with the company expecting continued momentum through the remainder of 2026.
Year to date, shares of Alkermes have rallied 75.9% compared with the industry’s rise of 6.4%.
Image Source: Zacks Investment Research
ALKS’ Strong Product Portfolio Aids Growth
In the first six months of 2026, Vivitrol and Aristada generated sales of $236.9 million and $190.5 million, respectively, up 6.4% and 9% year over year. Sales of both drugs benefited from underlying demand.
Notably, growth in the alcohol-dependence treatment market has helped drive new patients toward Vivitrol, while Aristada continues to generate steady sales.
In the first six months of 2026, Lybalvi generated sales of $186.3 million, up 20.7% year over year, driven by an increase in total prescriptions.
Alkermes added the narcolepsy drug Lumryz to its portfolio following the acquisition of Avadel Pharmaceuticals in February 2026. Lumryz generated $136.1 million in revenues during the first six months of 2026 following its addition to Alkermes’ portfolio.
Reflecting the growing momentum across its product portfolio, Alkermes expects Vivitrol sales to be in the range of $460-$480 million, while Aristada sales are anticipated in the range of $365-$385 million in 2026.
Lybalvi sales are expected to be in the range of $380-$400 million, while Lumryz sales are expected to be in the range of $315-$335 million in 2026.
ALKS' Ongoing Pipeline Development Activities
Alkermes is developing alixorexton, a novel, investigational, oral, selective orexin 2 receptor agonist for treating narcolepsy type 1 (NT1) and narcolepsy type 2 (NT2) in late-stage studies, as well as idiopathic hypersomnia (IH) in a mid-stage study.
In June 2026, the FDA granted orphan drug designation (ODD) to alixorexton for the treatment of IH. The European Commission also granted ODD to alixorexton for the treatment of patients with narcolepsy.
With certain clinical milestones expected later this year, successful development and potential approval of alixorexton could provide Alkermes with an additional long-term growth opportunity.
The consistent growth of its proprietary product portfolio, coupled with continued clinical progress with alixorexton, provides Alkermes with multiple growth drivers. These catalysts could support the company’s long-term growth prospects and help maintain positive momentum in the stock.
Alkermes plc Price
Alkermes plc price | Alkermes plc Quote
ALKS' Zacks Rank & Stocks to Consider
Alkermes currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have gained 0.6% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 154.1% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.